Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours

Yada Kanjanapan; Prunella Blinman; Craig Underhill; Deme Karikios; Eva Segelov; Desmond Yip

doi:10.1111/imj.15339

Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours

Yada Kanjanapan^*, Prunella Blinman, Craig Underhill, Deme Karikios, Eva Segelov, Desmond Yip

^*Corresponding author for this work

School of Medicine and Psychology

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

People with cancer are vulnerable to increased morbidity and mortality from the coronavirus disease 2019 (COVID-19). COVID-19 vaccination is key to protecting the population of people with cancer from adverse outcomes of SARS-CoV-2 infection. The Medical Oncology Group of Australia aimed to address the considerations around COVID-19 vaccination in people with cancer, in particular, safety and efficacy of vaccination. The assessment of patients with generalised allergic reaction to anti-cancer therapy containing vaccine components and practical implementation of vaccination of people on active anti-cancer therapy are also discussed.

Original language	English
Pages (from-to)	955-959
Number of pages	5
Journal	Internal Medicine Journal
Volume	51
Issue number	6
DOIs	https://doi.org/10.1111/imj.15339
Publication status	Published - Jun 2021

Access to Document

10.1111/imj.15339

Cite this

@article{488027c9539045d1b6e83199ddd51dec,

title = "Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours",

abstract = "People with cancer are vulnerable to increased morbidity and mortality from the coronavirus disease 2019 (COVID-19). COVID-19 vaccination is key to protecting the population of people with cancer from adverse outcomes of SARS-CoV-2 infection. The Medical Oncology Group of Australia aimed to address the considerations around COVID-19 vaccination in people with cancer, in particular, safety and efficacy of vaccination. The assessment of patients with generalised allergic reaction to anti-cancer therapy containing vaccine components and practical implementation of vaccination of people on active anti-cancer therapy are also discussed.",

keywords = "COVID-19, cancer, immunosuppression, vaccination",

author = "Yada Kanjanapan and Prunella Blinman and Craig Underhill and Deme Karikios and Eva Segelov and Desmond Yip",

note = "Publisher Copyright: {\textcopyright} 2021 Royal Australasian College of Physicians",

year = "2021",

month = jun,

doi = "10.1111/imj.15339",

language = "English",

volume = "51",

pages = "955--959",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "John Wiley \& Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Medical Oncology Group of Australia position statement

T2 - COVID-19 vaccination in patients with solid tumours

AU - Kanjanapan, Yada

AU - Blinman, Prunella

AU - Underhill, Craig

AU - Karikios, Deme

AU - Segelov, Eva

AU - Yip, Desmond

PY - 2021/6

Y1 - 2021/6

N2 - People with cancer are vulnerable to increased morbidity and mortality from the coronavirus disease 2019 (COVID-19). COVID-19 vaccination is key to protecting the population of people with cancer from adverse outcomes of SARS-CoV-2 infection. The Medical Oncology Group of Australia aimed to address the considerations around COVID-19 vaccination in people with cancer, in particular, safety and efficacy of vaccination. The assessment of patients with generalised allergic reaction to anti-cancer therapy containing vaccine components and practical implementation of vaccination of people on active anti-cancer therapy are also discussed.

AB - People with cancer are vulnerable to increased morbidity and mortality from the coronavirus disease 2019 (COVID-19). COVID-19 vaccination is key to protecting the population of people with cancer from adverse outcomes of SARS-CoV-2 infection. The Medical Oncology Group of Australia aimed to address the considerations around COVID-19 vaccination in people with cancer, in particular, safety and efficacy of vaccination. The assessment of patients with generalised allergic reaction to anti-cancer therapy containing vaccine components and practical implementation of vaccination of people on active anti-cancer therapy are also discussed.

KW - COVID-19

KW - cancer

KW - immunosuppression

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=85108277414&partnerID=8YFLogxK

U2 - 10.1111/imj.15339

DO - 10.1111/imj.15339

M3 - Article

SN - 1444-0903

VL - 51

SP - 955

EP - 959

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 6

ER -

Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours

Abstract

Access to Document

Other files and links

Fingerprint

Cite this